Novartis Eyes Job Cuts, Plans for $1.22 Billion Hit on Pipeline, Patent Setbacks
Novartis is looking to job cuts and charges of $1.22 billion to help it weather withering revenues from the coming patent loss of blockbuster hypertension drug Diovan and possible slashed sales of Tekturna, which performed poorly in a recent clinical trial.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.